Moderna, Inc.

NASDAQ:MRNA

Biotechnology

Healthcare
$196.79 +4.01%

+$2.48 today

Market cap
$79.63B
Beta
1.03
P/E (TTM)
-7.9
EPS (TTM)
-$8.09
52W Low $22.28High $67.74

Volume 6.91M

Average 6.53M

MRNA EBITDA Margin

EBITDA as a percentage of revenue.

Moderna, Inc.NASDAQ: MRNA

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin widens to 18.2%

EBITDA Margin was 18.2% in Q3 FY2026, up 31.5 pp from a year earlier. On a trailing-twelve-month basis it was -97.2%, up 35.0 pp year over year. Over 3 fiscal years it narrowed by 184.1 pp.

Context

  • EBITDA Margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 14 analysts of -115.4% for the fiscal year ending Dec 2026, up from -131.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
18.2%+503.7 pp QoQ
Last fiscal yearDec 2025
-131.3%-25.2 pp YoY
LTMSep 2026
-97.2%+35.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+31.5 pp-44.4 pp-75.9 pp
1 year-25.2 pp+16.0 pp+41.2 pp
3 years-184.1 pp+110.7 pp+294.7 pp
5 years+163.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-131.3%
Year-over-year change
-25.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How MRNA compares with its peers on the latest reported figures

  • MRNA's LTM Sep 2026 EBITDA Margin of -97.2% is the 6th highest of the 9 companies compared; the peer median is -46.6%.
  • Its year-over-year change of +35.0 pp is the 2nd highest of 9, against a peer median of -34.9 pp.
  • Over three fiscal years its change of -184.1 pp compares with a peer median of -56.1 pp.
MRNA Competitors Peer median
EBITDA Margin for MRNA and competitors
Company Period LTM level YoY 3-year change
GSKGSK plcLTM Jun 202626.5% -0.7 pp+2.5 pp
PFEPfizer Inc.LTM Jun 202621.2% -10.4 pp-13.7 pp
NVAXNovavax, Inc.LTM Mar 2026-7.1% -51.3 pp+81.6 pp
BNTXBioNTech SELTM Jun 2026-35.6% -34.2 pp-98.4 pp
VALNValneva SELTM Mar 2026-57.7% -35.6 pp+0.1 pp
MRNAModerna, Inc.LTM Sep 2026-97.2% +35.0 pp-184.1 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-148.9% -100.7 pp-100.7 pp
VIRVir Biotechnology, Inc.LTM Mar 2026-669.6% +2109.2 pp-668.6 pp
INOInovio Pharmaceuticals, Inc.FY2025-125425.9% -77690.7 pp-122786.1 pp
PCVXVaxcyte, Inc.FY2025— ——
Peer median (excluding MRNA) -46.6%-34.9 pp-56.1 pp

Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.74B18.88B6.85B3.2B1.94B
Cost of Revenue2.62B5.42B4.69B1.46B868M
Gross Profit15.12B13.46B2.16B1.74B1.08B
Gross Margin85.2%71.3%31.5%54.2%55.3%
Research & Development1.99B3.3B4.85B4.54B3.13B
Selling, General & Admin567M1.13B1.55B1.17B1.02B
Operating Expenses1.82B4.04B6.39B5.68B4.15B
Depreciation & Amortization232M348M621M189M215M
EBITDA13.54B9.95B(3.28B)(3.39B)(2.55B)
EBITDA Margin76.3%52.7%-47.9%-106.1%-131.3%
Operating Income13.3B9.42B(4.24B)(3.95B)(3.07B)
Operating Margin75.0%49.9%-61.9%-123.3%-158.1%
Interest Income18M200M421M425M314M
Interest Expense18M29M38M24M10M
Other Income / Expenses(11M)155M297M338M306M
Income Before Tax13.29B9.58B(3.94B)(3.61B)(2.77B)
Pre-Tax Margin74.9%50.7%-57.6%-112.8%-142.4%
Income Tax Expense1.08B1.21B772M(46M)54M
Net Income12.2B8.36B(4.71B)(3.56B)(2.82B)
Net Margin68.8%44.3%-68.8%-111.3%-145.2%
EPS (Basic)30.3121.26(12.34)(9.27)(7.26)
EPS (Diluted)28.2920.10(12.34)(9.27)(7.26)
Weighted Avg Shares403M394M382M384M389M
Weighted Avg Shares (Diluted)431M416M382M384M389M

Moderna, Inc.

NASDAQ:MRNA

Intrinsic Alpha fair value

Locked

Current Price

$196.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.